A single injection that might potentially replace the multiple hospital visits required for current Alzheimer's medications is showing encouraging results in laboratory mice, according to a new scientific study that researchers believe could transform future Alzheimer's treatment. 

The experimental therapy, created by scientists at Washington University School of Medicine in St Louis, and published  in the journal Science recently, converts normal brain support cells into plaque-destroying machines. While the method has only been tested in mice, experts believe it provides a promising roadmap for future human trials. 

Researchers have now demonstrated that the newest Alzheimer's medications, known as monoclonal antibodies, can slow down the progression of the disease. These medications work by eliminating amyloid beta, a sticky protein that accumulates in the brain and forms plaques, which are thought to harm nerve cells and cause memory loss. According to studies, these medications can let a patient live independently for an additional ten months. 

However, these therapies impose a substantial burden. Patients must attend hospitals every two to four weeks for high-dose intravenous infusions, which is a taxing regimen that can last indefinitely. Families frequently have to plan transportation and caregiving support for each appointment. 

The new experimental strategy promises to simplify this process greatly. 

Instead of numerous infusions, researchers used a harmless virus to deliver a gene to mice's brain cells with a single injection. This gene directs common brain cells, known as astrocytes, to form a molecular "homing device" known as a chimeric antigen receptor, or CAR. 

To put it simply, scientists claim the mutated astrocytes start acting like Pac-Man, the popular video game character, by crawling through brain tissue and selectively "chomping up" dangerous amyloid plaques while leaving healthy tissue alone. 

"This study marks the first successful attempt at engineering astrocytes to specifically target and remove amyloid beta plaques in the brains of mice with Alzheimer's disease," said Dr Marco Colonna, the study's senior author and a pathology professor at Washington University. 

He stressed that the therapy is still in its early stage. 

"Although more work needs to be done to optimise the approach and address potential side effects, these results open up an exciting new opportunity to develop CAR-astrocytes as an immunotherapy for neurodegenerative diseases and even brain tumours," claimed Colonna. 

In the tests, researchers injected the modified gene therapy into two groups of mice that were genetically predisposed to Alzheimer's disease. One group received treatment before plaques formed, whereas the other group already had plaque-filled brains. 

Three months later, the younger treated mice were entirely plaque-free, while older animals showed a 50% reduction in dangerous protein deposits. 

The technique also helps to address a critical biological issue in Alzheimer's disease. Normally, specific immune cells known as microglia remove trash from the brain. However, excessive amyloid formation frequently overwhelms these cells in Alzheimer's sufferers. 

By converting astrocytes, the most numerous brain cells, into extra cleaning units, researchers successfully recruited more workers to help clear the hazardous protein. 

Experts believe the potential benefits extend beyond the laboratory results. If equivalent results are obtained in humans, a single injectable therapy could greatly reduce the treatment load on patients and carers who are currently required to visit hospitals for infusion therapy. 

The research team has already filed a patent for the modified cell technique and intends to develop the therapy further to assure safety before proceeding to human trials. 

Scientists are also looking into an additional potential option. By tweaking the CAR "homing beacon" to detect markers on cancer cells, the same technique could potentially be used to locate and destroy brain tumours. 

For now, researchers emphasise that the treatment is only experimental. However, the concept of transforming the brain's own cells into specialised cleaners could open up new avenues in the fight against Alzheimer's disease, potentially transforming a lifelong hospital regimen into a single, potent treatment.